Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castration-resistant prostate cancer and led to updates in the NCCN Guidelines for this disease.
Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.
Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.
Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.
Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.
